The Zalicus preclinical pipeline includes multiple drug candidates targeted for potential development in multiple pain and immuno-inflammatory diseases, oncology and potentially other therapeutic areas.

 

Ion Channel Programs

The N-type and T-type calcium channels in cells are important to the regulation of the body’s nervous and cardiovascular systems. Zalicus is developing proprietary compounds to potentially treat pain and other diseases by selectively blocking these calcium channels. The calcium channel programs are believed to have the potential to produce a new class of analgesics for the treatment of both acute and chronic pain, with potential safety and efficacy advantages over existing analgesics. Read More